Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa doxycycline in advanced intrahepatic cholangiocarcinoma after progression on chemotherapy plus PD-1 therapy
ChiCTR2400085250Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxycycline in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Safety, Tolerability and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
doxycycline
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400085250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085250.